
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Democrats are determined to enact legislation that will ensure patient access to certain services and benefits from managed care plans.
over 25 years ago
Pharmacies: OTC Price Warsover 25 years ago
One Disease at a Timeover 25 years ago
Overview of the Industry: A World of Opportunitiesover 25 years ago
A Giant Stumblesover 25 years ago
Overruled: No More Dual Pricingover 25 years ago
Submergedover 25 years ago
Generic Threat





